Accuray Incorporated (ARAY)
| Market Cap | 429.90M |
| Revenue (ttm) | 378.68M |
| Net Income (ttm) | 13.59M |
| Shares Out | 91.19M |
| EPS (ttm) | 0.15 |
| PE Ratio | 31.73 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $4.76 |
| Previous Close | $4.75 |
| Change ($) | 0.01 |
| Change (%) | 0.21% |
| Day's Open | 4.96 |
| Day's Range | 4.67 - 4.98 |
| Day's Volume | 928,316 |
| 52-Week Range | 1.35 - 5.00 |
SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showe...
SUNNYVALE, Calif., Jan. 8, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2021, ended December 31, 2020, after the...
Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.
SUNNYVALE, Calif., Jan. 6, 2021 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced its participation in the 39th J.P. Morgan Annual Healthcare Conference. Josh Levine, Preside...
SUNNYVALE, Calif., Jan. 5, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (F...
This year has been a remarkable one for cheap stocks, many of which have enjoyed contrarian upside. However, there are still more opportunities to be had for the intrepid speculator.
Accuray (ARAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
SUNNYVALE, Calif., Dec. 3, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Jim Dennison, the comp...
Does Accuray (ARAY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Accuray's (ARAY) new deal with DHL Supply Chain will help in the delivery of advanced cancer treatment technology.
SUNNYVALE, Calif. and WESTERVILLE, Ohio, Nov. 18, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and DHL Supply Chain announced today they have entered into a global service parts lo...
SUNNYVALE, Calif., Nov. 12, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Jim Dennison as its senior vice president of global quality and regulatory...
SUNNYVALE, Calif., Nov. 10, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that innovations in hardware and software solutions and clinical data presented at this yea...
LONDON--(BUSINESS WIRE)-- #GlobalHeadandNeckCancerDiagnosticsMarket--The Head and Neck Cancer Diagnostics Market will grow by USD 3.41 bn during 2020-2024
Accuray (ARAY) registered growth in Service revenues in Q1.
Fiscal first quarter revenue was a little better than expected, and management did well on costs, achieving a modest profit where a modest loss had been expected. Orders were down, not surpris...
Accuray Incorporated (ARAY) CEO Josh Levine on Q1 2021 Results - Earnings Call Transcript
Accuray (ARAY) delivered earnings and revenue surprises of 100.00% and 10.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.
SUNNYVALE, Calif., Oct. 19, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Mike Leischer as its vice president and general manager, Americas (AMS) re...
These three MedTech stocks are expected to grow post their Q3 earnings release.
Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.
Robotics stocks represent innovation, technology and future profitability. For investors interested in those promises, click to read on.
The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.
SUNNYVALE, Calif., Sept. 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Japan are using the Radixact® System with the Synchrony® Automat...
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
SUNNYVALE, Calif., Sept. 10, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Joshua H.
SUNNYVALE, Calif., Sept. 1, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at University Hospital Città della Salute e della Scienza, in Tu...
Accuray Idling On The Runway Ahead Of A Significant Chinese Revenue Launch
Accuray (ARAY) registered decline in Product and Service revenues in Q4
Accuray Incorporated (ARAY) CEO Joshua Levine on Q4 2020 Results - Earnings Call Transcript
Shares of Accuray (NASDAQ:ARAY) rose 1.66% in after-market trading after the company reported Q4 results.
SUNNYVALE, Calif., Aug. 13, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2020.
On Thursday, August 13, Accuray (NASDAQ: ARAY) will release its latest earnings report.
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SUNNYVALE, Calif., July 22, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Anne B.
SUNNYVALE, Calif., July 16, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and the 2020 fiscal year, ended June 30, 2020 after th...
In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.
Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
SUNNYVALE, Calif., June 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has launched the CyberKnife® S7™ System, an innovative device combining speed, ...
Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
The coronavirus-led 'new normal' has altered several businesses. Here are three sectors that will see a boom in the near future.
Since the coronavirus outbreak, robots have filled up several job vacancies caused by social distancing orders. Here are five robotics and related stocks investors should closely watch.
Accuray (ARAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Accuray (ARAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
COVID-19 Saps Some Of Accuray's Momentum, But Execution Remains Strong
About ARAY
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during ... [Read more...]
| Industry Medical Devices | IPO Date Feb 8, 2007 |
| CEO Joshua Levine | Employees 932 |
| Stock Exchange NASDAQ | Ticker Symbol ARAY |
Analyst Forecasts
According to 5 analysts, the average rating for Accuray stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 47.06% from the latest price.